Kornimate/medical-research-clean huggingface dataset:
hyperventilation in patients with chronic low back pain

Conditions: Low Back Pain, Recurrent; Hyperventilation Syndrome

Summary: low back pain (lbp) is the leading cause of disability worldwide. impaired postural control is a key factor in the development and maintenance of lbp. moreover, the prevalence of lbp is associated with impairments in diaphragm function, symptoms of dyspnea, and dysfunctional breathing. however, the association between lbp (and more specifically postural control) and hyperventilation remains unknown. the main objective of this project is to investigate whether the presence of recurrent non-specific lbp is related to the presence of hyperventilation, when classified either objectively by decreased carbon dioxide values (demonstrating hypocapnia) or by symptoms while showing normal carbon dioxide values. moreover, the investigators will explore whether psychosocial factors play a role in this relation. subsequently, the investigators will examine whether hyperventilation in lbp patients is related to impaired postural control, and more specifically to a decreased postural contribution of the diaphragm.


Eligibility criteria:
inclusion criteria patients: * chronic primary low back pain (\>12 weeks) as diagnosed by a medical doctor inclusion criteria healthy controls: * no low back pain exclusion criteria: * insufficient understanding of dutch language * previous spinal surgery * chronic obstructive lung disease, interstitial lung disease, pulmonary vascular disease, asthma except for exertional asthma * acute cardiovascular or gastrointestinal disorders * neuromuscular disease interfering with normal lower limb or trunk functioning * acute pain or secondary chronic pain * pregnant and lactating women * major psychiatric conditions * acute lower limb problems * vestibular disorders
a study of ly3502970 in japanese participants with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: the main purpose of this study is to learn about the side effects of ly3502970 when given to japanese participants with type 2 diabetes mellitus (t2dm). blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. for each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.


Eligibility criteria:
inclusion criteria: * males and females not of childbearing potential * have type 2 diabetes mellitus (t2dm) diagnosed for at least 1 year * have glycated hemoglobin (hba1c) value ≥ 7.0% and ≤ 10.0% for participants treated with diet and exercise or hba1c ≥ 6.5% and ≤ 9.0% for participants who have washed out antidiabetic medications at screening * have type 2 diabetes controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (oam); either metformin, dpp-4 (dipeptidyl peptidase-4) inhibitor, or sglt2 (sodium-glucose co-transporter-2) inhibitor within 3 months prior to screening. participants must withdraw from their oam treatment for at least 28 days prior to dosing. exclusion criteria: * have type 1 diabetes mellitus or latent autoimmune diabetes in adults. * have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization * have had an episode of severe hypoglycemia, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery or have a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms. * have a history of acute or chronic pancreatitis or fasting serum triglyceride level of \>500 milligram per deciliter (mg/dl). * have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or have elevations in aminotransferases (alanine aminotransferase \[alt\] and aspartate aminotransferase \[ast\]) greater than 3× upper limit of normal (uln).
10mg zd4054 (zibotentan) pk study in male, elderly chinese patients with advanced solid malignancies

Conditions: Advanced Solid Malignancies

Summary: the purpose of this study is to assess the pharmacokinetics of single and multiple doses of 10mg zd4054 (zibotentan) in male, elderly chinese patients with advanced solid malignancies.


Eligibility criteria:
inclusion criteria: * provision of informed consent * histological and/or cytological confirmed advanced solid malignancies * who performance status\<2 exclusion criteria: * history of significant gastrointestinal impairment, as judged by the investigator, that could significantly affect the absorption of zd4054 (zibotentan) , including the ability to swallow the tablet whole. * alt or ast³2.5 ´ulrr. if liver metastases are present alt or ast more than 5times ulrr, serum bilirubin \> 1.5 x ulrr, serum creatinine\>1.5 x ulrr or creatinine clearance of \<50ml/min calculated by cockroft-gault * recent (\<14 days) major surgery prior to entry into the study, or a surgical incision that is not fully healed, radical radiotherapy within the previous 4 weeks, or unresolved acute or subacute toxicities from prior radiotherapy

Keywords: phase i, advanced solid malignancies, advance solid tumour advanced cancer zd4054 (zibotentan) china pk pharmacokinetics
trial of therapeutic cancer vaccine ose2101 in patients with non-small cell lung cancer and secondary resistance to immune checkpoint inhibitor

Conditions: Patients With Non-Small Cell Lung Cancer

Summary: multicenter, randomized (2:1), open-label phase 3 study in hla-a2 positive patients with squamous and non-squamous metastatic nsclc with ici secondary resistance. patients will be randomized into 2 arms (randomization 2:1): experimental arm a with ose2101 monotherapy or control arm b soc with docetaxel monotherapy. stratification factors will be histology (squamous versus non squamous) and ecog performance status (0 versus 1).


Eligibility criteria:
inclusion criteria: 1. male or female, aged ≥ 18 years 2. patients expressing hla-a2 phenotype in blood by pre-screening central laboratory 3. patients with histologically or cytologically squamous or non-squamous documented nsclc, metastatic stage at study entry, not eligible for definite surgery or radiation, without egfr, alk and ros1 gene alterations eligible for targeted therapy; other sensitizing mutations known to be immunosensitive are eligible in case of lack of local access to targeted therapy (i.e.; kras g12c and braf mutations) after sponsor's agreement 4. patients with secondary resistance to ici; other inclusion and exclusion criteria will apply per protocol.

Keywords: immune checkpoint inhibitor cancer vaccine non-small cell lung cancer
clinical study on the treatment of mibc patients with shr-a2102 injection combined with adebrelimab (shr-1316)

Conditions: Muscular Invasive Bladder Cancer (MIBC)

Summary: in phase ii, the main objective is to evaluate the efficacy of shr-a2102 combined with adebrelimab in the treatment of muscular invasive bladder cancer (mibc); the main objective of phase iii is to evaluate the efficacy of shr-a2102 for injection combined with adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (mibc).


Eligibility criteria:
inclusion criteria: 1. age over 18 years old, gender not limited. 2. the patient voluntarily joined this study and signed informed consent 3. ecog score is 0 or 1 4. expected survival period ≥ 2 years. 5. pathology and imaging diagnosis of non metastatic muscle invasive bladder cancer 6. there are assessable lesions that meet the recist 1.1 criteria 7. enough organ function exclusion criteria: 1. received systemic anti-tumor therapy 4 weeks before starting the study treatment 2. the toxicity and/or complications of previous anti-tumor treatments have not recovered to nci-ctcae ≤ 1 level 3. subjects known or suspected to have interstitial pneumonia 4. individuals with any active, known or suspected autoimmune diseases 5. there are clinical symptoms or diseases of the heart that have not been well controlled 6. diagnosed with any other malignant tumor 7. subjects who have experienced severe infections within 28 days prior to their first medication use 8. history of immunodeficiency 9. use of attenuated live vaccine within 28 days prior to the first study medication 10. have undergone major surgery within 28 days prior to the first administration of medication
telemedicine-based, multidisciplinary-team, intervention to reduce unnecessary hospitalizations

Conditions: Dementia Alzheimers; Disruptive Behavior

Summary: the purpose of this study is to investigate the use of telemedicine-based intervention at urban and rural skilled nursing facilities to recommend multidisciplinary dementia care to residents with dementia who are at risk for unnecessary hospitalization due behavioral or neuropsychiatric symptoms and/or complications as well as caregivers and facility staff. the multidisciplinary team is comprised of trained behavioral neurologists, social workers, advanced practice providers, primary medical team and nurse coordinators.


Eligibility criteria:
inclusion criteria: dementia care facility resident problematic behavioral problems exclusion criteria: none
a comparative efficacy study: treatment for non-healing diabetic foot ulcers

Conditions: Foot Ulcer, Diabetic

Summary: the primary objective of this study is to assess the effectiveness of matristem devices compared to cellular dermal replacement tissue, for the treatment of non-healing diabetic foot ulcers.

due to their characteristically poor healing capacity, diabetic foot ulcers (dfus) are challenging for clinicians to treat. this prospective, multi-center clinical study will examine outcomes following treatment of dfus, with one of two fda cleared tissue-engineered devices, matristem® or cellular dermal replacement tissue, on dfus that have demonstrated an inadequate response to initial standard of care therapy. the incidence of ulcer closure, rate of wound closure, and quality of life will be evaluated over a eight week period.

Eligibility criteria:
major inclusion criteria: * subject has a current diagnosis of type i or type ii diabetes * subject's ulcer is on the forefoot or heel * subject has chronic ulcer - has been present for minimum of 4 weeks * subject's ulcer extends through the dermis and into the subcutaneous tissue * subject's hgba1c \<12% * subject has adequate circulation to the study foot as evidenced by a doppler measured abi greater than or equal to 0.7after 10 minutes rest major exclusion criteria: * subject has a known sensitivity to bovine- or porcine-derived products. * subject's ulcer is due to a non-diabetic etiology * subject's ulcer is over a charcot deformity of the mid-foot * subject's random blood sugar readings are \>450 mg/dl * subject is on dialysis * subject has a non-study ulcer on the study limb located within 7.0 cm of the study ulcer
a prospective double-blind study of retrovir in early hiv infection

Conditions: HIV Infections

Summary: to evaluate the safety and tolerance of chronic administration of retrovir (azt) to adult patients with early manifestations of hiv disease. to assess the efficacy of azt therapy in the treatment of hiv disease in these patients. (12/01/89) information supplied by drug company update. study discontinued due to positive data from actg 016.


Eligibility criteria:
inclusion criteria concurrent treatment: allowed: * electron beam therapy to an area of less than 100 cm2. patient must have signs and symptoms of hiv infection confined to those of stages wrii-v or cdc groups iii iv-a, iv-c-2 (except recurrent salmonella bacteremia, nocardiosis, or disseminated/extrapulmonary mycobacterium tuberculosis), and iv-e (except diffuse interstitial lymphoid pneumonitis). * patient must be able to give informed consent. exclusion criteria co-existing condition: patients with the following are excluded: * evidence of nervous system dysfunction caused by factors other than hiv infection, including chronic alcohol or drug abuse. * present or prior known aids-defining opportunistic infections, lymphomas, or malignancies based on cdc criteria. * present or prior known systemic opportunistic diseases most recently included in the expanded cdc definition of aids: * extrapulmonary or disseminated mycobacterium tuberculosis infections, recurrent nontyphoidal salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid pneumonitis. * evidence of compromised bone marrow function defined by specified lab values. * evidence of hiv neurologic disease. * evidence of hiv-associated "wasting syndrome". * hypersensitivity to zidovudine (azt). concurrent medication: excluded: * cytotoxic chemotherapeutic agents. * steroids. * interferon or immunomodulating agents. * any antiretroviral drug including, but not limited to zidovudine (azt), ribavirin, hpa23, al 721, or phosphonoformate. patients with the following are excluded: * evidence of nervous system dysfunction caused by factors other than hiv infection, including chronic alcohol or drug abuse. present or prior known aids-defining opportunistic infections, lymphomas, or malignancies based on cdc criteria. present or prior known systemic opportunistic diseases most recently included in the expanded cdc definition of aids: * extrapulmonary or disseminated mycobacterium tuberculosis infections, recurrent nontyphoidal salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid pneumonitis. * evidence of compromised bone marrow function defined by specified lab values. evidence of hiv neurologic disease. * evidence of hiv-associated wasting syndrome. * hypersensitivity to retrovir. prior medication: excluded within 4 weeks of study entry: * interferon. * immunomodulating agents. * myelosuppressive drugs. * nephrotoxic agents. * other experimental chemotherapy. prior treatment: excluded: * treatment with radiation therapy (with the exception of electron beam therapy to an area of less than 100 cm2). chronic alcohol or drug abuse.

Keywords: prospective studies zidovudine
efficacy of premixed nitrous oxide and oxygen in patient with out-of-hospital moderate acute pain

Conditions: Acute Pain

Summary: less than 10% of patients with a traumatic pain have been managed by a physician before to be admitted in an emergency service. 50 % of those patients have been carried by paramedics. premixed nitrous oxide and oxygen is often used by paramedics, but no scientific studies have demonstrated its efficacy. the aim of the study is to demonstrate the efficacy of premixed nitrous oxide and oxygen in patients with out-of-hospital moderate acute pain.

the study will evaluate the efficacy of premixed nitrous oxide and oxygen (meopa) in patients with out-of-hospital moderate acute pain. the primary endpoint is the percentage of patients with pain relief (with a numerical rating scale of 3/10 or lower) 15 minutes after randomisation. secondary endpoints are treatment safety and adverse events, time to analgesia and duration of analgesia. this study will expect 60 patients assigned in two parallel groups, defined by a randomization scheme. group assignments were sealed in opaque envelopes and will be open sequentially by the dispatcher when the paramedic is ready to include the patient. the letter contained in the envelope corresponds to the cylinder to use. eligible patients with a numeric rating scale (nrs) score between 3 and 6/10 are randomly allocated to receive either meopa, or medical air. fifteen minutes after the randomisation, all patients will receive meopa from a distinct cylinder. pain score will be measured at baseline and every 5 minutes until pain relief will be obtained. the paramedic blinded to the analgesic treatment groups will do all assessments of patients. the safety evaluation will include non invasive monitoring of blood pressure, heart rate, oxygen saturation by pulse oximetry (spo2) and adverse events collection.

Eligibility criteria:
inclusion criteria: * patients aged 18 years old * patients with a moderate acute pain (nrs score between 3 and 6) exclusion criteria: * contraindication of premixed 50% nitrous oxide and oxygen * recent treatment of analgesic (less than 6 hours)

Keywords: premixed nitrous oxide and oxygen acute pain prehospital setting
effect of cooling therapy for post-operative pain in open carpal tunnel release

Conditions: Carpal Tunnel Syndrome; Perioperative/Postoperative Complications

Summary: this study seeks to perform an appropriately-powered study to evaluate any clinical difference between continuous cooling therapy and traditional ice for treatment of post-operative pain in open ctr surgery.

post-operative pain control is paramount to all operative procedures and involves several modalities. both pharmaceutical and non-pharmaceutical measures are frequently used. carpal tunnel release (ctr) surgery is one of the most common surgeries performed in the u.s. with over 400,000 procedures per year.2 frequently, ice is used as a treatment modality following surgical ctr.3 several products have been developed in the past decades to improve ice therapy in the rehabilitation period. one such product is the polar care which provides up to 6-8 hours of continuous icing. while there is good data supporting the use of cooling therapy (ice) for post-operative pain, there is lack of data surrounding the use of continuous cooling therapy machines such as the polarcare following carpal tunnel release (ctr). the two papers that evaluated the efficacy of continuous cooling therapy following ctr had conflicting results on any added benefit of continuous cooling therapy over traditional icing. there is no standard of care for post-operative icing at ucmc following ctr. clinicians currently decide whether to give patients a polarcare machine on the day of surgery without any algorithm. all other patients are encouraged to use traditional icing methods. this study seeks to perform an appropriately-powered study to evaluate any clinical difference between continuous cooling therapy and traditional ice for treatment of post-operative pain in open ctr surgery. the investigators hypothesize that participants receiving continuous cooling therapy will have a statistically significantly lower pain score compared to those receiving traditional ice therapy.

Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. indicated for open carpal tunnel release 3. able and willing to complete online questionnaires exclusion criteria: 1. prior carpal tunnel surgery for ipsilateral extremity 2. additional procedures to be performed on ipsilateral or contralateral extremity 3. current opioid or narcotic pain medication usage
diclofenac gel in the treatment of cervicogenic headache

Conditions: Cervicogenic Headache

Summary: the intervention will consist of the nursing staff applying 2 grams of diclofenac 1% gel topically to the posterior cervical region four times daily. the control group will receive petroleum jelly topically to the posterior cervical region four times daily. patients will receive a pre-intervention and post-intervention survey incorporating the numeric assessment scale and headache impact test-6.


Eligibility criteria:
inclusion criteria: 1. 18-90 years old 2. subject must be able to consent for themselves 3. hospitalized at loma linda east campus rehabilitation hospital 4. english or spanish speaking 5. complain of a headache, caused by a disorder of the cervical spine and/or it's component (i.e. bony, disc and/or soft tissue elements) usually but not invariably accompanied by neck pain (avijgan et al, 2019)). exclusion criteria: 1. primary headache secondary to intracranial pathology (i.e. tumors) a. while tbi and stroke patients can suffer headaches as a sequalae of their intracranial pathologies, it is not always the case that their headache is primarily secondary to their pathology but due to other etiologies such as cervicogenic headache or myofascial pain syndrome. history and physical examination by the medical team will help aid in determining the headache's etiology. 2. patients on dual antiplatelet therapy a. aspirin 81mg daily or clopidogrel (or antiplatelet monotherapy) is acceptable 3. history of cervical spine procedures a. spinal cord injury patients with cervical neck injuries that have required operative repair will be excluded from the study. 4. nerve blocks within past 4 weeks or steroid injections within past 6 months. 5. patients with fibromyalgia 6. pregnant women 7. chronic pain on continuous opiate regimen (use of opioids on most days \>90 days) 8. discharged in less than 14 days from acute inpatient rehabilitation 9. any contraindication use per diclofenac gel package insert: 1. known hypersensitivity to diclofenac or any other components of the drug product 2. history of asthma, uriticaria, or other allergic-type reactions after taking aspirin or other nsaids. 3. in the setting of coronary artery bypass graft (cabg) surgery. 10. development of adverse reaction resulting in discontinuation of diclofenac gel

Keywords: headache cervicogenic diclofenac
tdcs and aphasia treatment

Conditions: Aphasia

Summary: this project will investigate the use of noninvasive brain stimulation in the form of tdcs (transcranial direct current stimulation) in conjunction with speech-language therapy, for the improvement of language production in stroke survivors with aphasia. the hypothesis is that anodal tdcs and speech-language therapy will facilitate improved outcomes compared to speech therapy alone.

aphasia, commonly defined as impairment or loss of language functions, is a frequent and often chronic consequence of stroke, with detrimental effects on patient autonomy and health-related quality of life (hrqol). although beneficial in some cases, the effectiveness of behavioral therapy is often limited, and therefore new complementary treatments must be developed in order to improve rehabilitation of post-stroke aphasia. in most individuals, language areas in the brain are localized in the left hemisphere. after stroke, there is evidence that the brain reorganizes such that either areas close to damaged language areas in the left hemisphere, or anatomically similar areas in the right hemisphere, are recruited to perform language tasks. recently, studies have begun to examine the effects of non-invasive brain stimulation on aphasia rehabilitation. one such technique is transcranial direct current stimulation (tdcs), which involves administering weak electrical currents through surface electrodes on the scalp. the effects can either stimulate an area, or inhibit an area of the brain. the main hypothesis is that stimulating language areas in the left hemisphere in conjunction with speech language therapy will facilitate reorganization of language-relevant areas of the brain, and improve expression. the proposed study will compare the effects of transcranial direct current stimulation (tdcs) activating language centers in the left hemisphere and sham tdcs, in right-handed individuals with chronic post-stroke aphasia. this study will provide information on the effects of tdcs, in conjunction with speech-language therapy, on aphasia rehabilitation.

Eligibility criteria:
inclusion criteria: single left hemisphere stroke, more than three months post stroke, right handed, no other medical problems, ages 18-100 - exclusion criteria: more than one stroke, less than three months post stroke, other medical problems, pacemaker or other electronic implant (e.g. hip replacement), pregnancy -

Keywords: aphasia therapy stroke language naming quality of life tdcs treatment